[Administration of moclobemide++ in children with attention deficit hyperactivity disorder ].
ADHD is a frequent disorder that occurs among approximately 5-10% of school children. Treating this syndrome, pharmacotherapy with different forms of psychotherapy are applied. In many European countries and in the USA the primary medicines are the psychostymulative ones; in Poland, however, they are not registered in the Pharmacopeia. Thus, what seems to be important is seeking other drugs that can be useful in ADHD treatment. In the Child and Adolescent Psychiatry Clinic in Poznań, a group of 15 children (13 boys, 2 girls) at the age of 6-13 were recognised to have ADHD; they were administered moclobemid (Aurorix) in dose of 75-225 mg/d throughout the period of 8 weeks. The medicine efficacy was being estimated with psychometric, questionnaire, and experimental methods. After 4 weeks, the drug ceased to be administered to two children due to complete lack of improvement or deterioration in functioning. It was observed that in the rest of the children their attention and hyperactivity functioning improved significantly. It is essential that the medicine was well tolerated and undesirable symptoms occurred rarely.
Antkowiak
R
R
Kliniki Psychiatrii Dzieci i Młodziezy AM w Poznaniu.
Rajewski
A
A
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D001549:Benzamides / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide